Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

During the coronavirus disease 2019 (COVID-19) pandemic, a wave of rapid and
collaborative drug discovery efforts took place in academia and industry, culminating in …

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Omicron sublineages, including the BA. 2-derived BA. 2.75. 2 and the BA. 5-derived BQ. 1.1 …

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine | New
England Journal of Medicine Skip to main content The New England Journal of Medicine …

Abstract BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that
encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has …

A safe and effective vaccine against COVID-19 is urgently needed in quantities that are
sufficient to immunize large populations. Here we report the preclinical development of two …

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—a new coronavirus that
has led to a worldwide pandemic—has a furin cleavage site (PRRAR) in its spike protein …

We engineered three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
viruses containing key spike mutations from the newly emerged United Kingdom (UK) and …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve
around the world, generating new variants that are of concern on the basis of their potential …